文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

Exagamglogene Autotemcel治疗重型镰状细胞病

Exagamglogene Autotemcel for Severe Sickle Cell Disease.
PubMed 文献 · N Engl J Med · 2024-04-24

这项3期单组开放标签研究纳入44例12至35岁重型镰状细胞病患者,采用CRISPR-Cas9编辑自体CD34+造血干/祖细胞(exa-cel)后回输。中位随访19.3个月,可评估的30例中29例(97%;95%CI 83至100)连续至少12个月无血管闭塞危象,30例(100%;95%CI 88至100)连续至少12个月无因血管闭塞危象住院,安全性总体与清髓性白消安预处理及自体造血干/祖细胞移植一致,未发生癌症。

要点

  • exa-cel通过CRISPR-Cas9编辑BCL11A红系特异性增强子区域重激活胎儿血红蛋白。
  • 可评估30例中29例(97%;95%CI 83至100)连续至少12个月无血管闭塞危象。
  • 30例(100%;95%CI 88至100)连续至少12个月无因血管闭塞危象住院。

核心结论

  • exa-cel治疗使97%的镰状细胞病患者在12个月或更长时间内消除血管闭塞危象。

研究设计与样本

  • 3期、单组、开放标签研究,纳入44例12至35岁、筛选前2年内每年至少发生2次严重血管闭塞危象的镰状细胞病患者。
  • CD34+造血干/祖细胞经CRISPR-Cas9编辑,回输前接受药代动力学剂量调整的白消安清髓性预处理。
  • 主要终点为连续至少12个月无严重血管闭塞危象,关键次要终点为连续至少12个月无因严重血管闭塞危象住院。

主要发现

  • 44例患者接受exa-cel,中位随访19.3个月(范围0.8至48.1)。
  • 每例患者中性粒细胞和血小板均植入。
  • 可评估的30例中29例(97%;95%CI 83至100)连续至少12个月无血管闭塞危象。
  • 30例(100%;95%CI 88至100)连续至少12个月无因血管闭塞危象住院(两项比较相对于50%应答无效假设的P<0.001)。
  • exa-cel安全性总体与清髓性白消安预处理及自体造血干/祖细胞移植一致,未发生癌症。

关键数值与推荐

  • 主要终点:可评估30例中29例(97%;95%CI 83至100)连续至少12个月无血管闭塞危象。
  • 关键次要终点:30例(100%;95%CI 88至100)连续至少12个月无因血管闭塞危象住院。
  • 两项终点相对于50%应答无效假设的P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A. METHODS: We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. RESULTS: A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. CONCLUSIONS: Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024. PMID: 38661449. doi:10.1056/NEJMoa2309676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。